Dr Wang on the Systemic Challenges Behind CAR T Access

In this episode of Community Corner, Michael Wang, MD, Puddin Clark Endowed Professor in the department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, explores the evolving landscape of chimeric antigen receptor T-cell (CAR T) therapy and the persistent barriers limiting its accessibility for patients in community settings. Once confined largely to major academic institutions, CAR T therapy is gradually expanding outward, yet significant challenges remain.

Dr Wang frames the issue through a philosophical lens, referencing traditional Chinese teachings to highlight the ideal hierarchy of medicine largely mirroring the primary, secondary, and tertiary levels of prevention. Reflecting on his role as a physician treating advanced disease, he emphasizes that broader societal and policy-level interventions are essential to truly improve patient outcomes.

A central concern discussed is the stark gap between eligibility and access. Despite being a potentially life-saving treatment, only an estimated 20% to 30% of eligible patients in the United States receive CAR T-cell therapy, with even lower rates reported in Europe. He underscores that this disparity is not solely a clinical issue but a systemic one, tied to insurance hurdles, high costs, and insufficient health policy support.

Ultimately, Dr Wang calls for coordinated efforts among healthcare providers, insurers, and policymakers to expand access, improve affordability, and ensure that groundbreaking therapies reach the patients who need them most.